Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The acquisition was announced on Monday with James Walker, CEO of Agostini’s Pharmaceutical Group, presents at MDJL’s Carifta ...

Kenya Medical Training College, in partnership with UNHCR, has announced 50 Community Health Nursing scholarships for Turkana ...

For instance, Novo Nordisk’s Rare Disease group ... AstraZeneca’s Alexion, which recently announced the building of a new rare disease development hub in Barcelona, is focused mostly on ...

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters ... Pharma major Novo Nordisk saw a lot of success with their launch of glucagon-like peptide-1 (GLP-1) drugs ...

Brii Biosciences, a Durham biotechnology company with global headquarters in China ... IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases ...

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...

Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...